-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed ---- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose --

Here is the original post:
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh